Background
Methods
Patients
Transplantation procedures
Definitions
Data collection
Statistical analysis
Results
Patients’ characteristics
Values (336) | |
---|---|
Gender [No. (%)] | |
Male | 215(64.0) |
Female | 121(36.0) |
Age [years] | |
< =14 | 223(66.4) |
> 14 | 113(33.6) |
Median (range) | 12 (2–55) |
Body weight(kg)median(range) | 37(10–82) |
Disease [No. (%)] | |
AML | 110(32.7) |
ALL | 177(52.7) |
CML | 16(4.8) |
MDS | 22(6.5) |
Others | 11(3.3) |
State of disease [No. (%)] | |
CR or Chronic phase | 257(76.5) |
NR or Advanced phase | 79(23.5) |
HLA match (low-resolution) [No. (%)] | |
4/6 | 113(33.6) |
5/6 | 168(50.0) |
6/6 | 55(16.4) |
Conditioning regimen [No. (%)] | |
Including TBI | 109(32.4) |
Not including TBI | 227(67.6) |
Total nucleated-cell dose, 107/kg median(range) | 4.17(1.71–13.90) |
Total CD34+ cell dose, 105/kg median(range) | 2.32(0.40–10.55) |
Incidence and aetiology of early BSI
Pathogens (n) | Isolates, n (%) |
---|---|
Gram-negative bacteria (60) | |
Escherichia coli | 39(38.6) |
Klebsiella pneumoniae | 9(8.9) |
Pseudomonas aeruginosa | 6(5.9) |
Sphingomonas paucimobilis | 1(1.0) |
Enterobacter cloacae | 1(1.0) |
Microbacterium flavescens | 2(2.0) |
Citrobacter freundii | 1(1.0) |
Acinetobacter baumanii | 1(1.0) |
Gram-positive bacteria(40) | |
Streptococcus viridans | 10(10.0) |
Staphylococcus epidermidis | 9(8.9) |
Enterococcus faecium | 7(6.9) |
Streptococcus mitis | 7(6.9) |
Streptococcus pluranimalium | 3(3.0) |
Gordona spp. | 1(1.0) |
Staphylococcus human | 1(1.0) |
Staphylococcus ear | 1(1.0) |
Gemella spp. | 1(1.0) |
Candida albicans(1) | 1(1.0) |
Antibiotics | Escherichia coli,% (n = 39) | Klebsiella pneumoniae, % (n = 9) | Pseudomonas aeruginosa, % (n = 6) | MDR bacteria, % (n = 37) |
---|---|---|---|---|
Amikacin | 12.8 | 44.4 | 0 | 18.9 |
Ampicillin | 100 | 100 | 33.3 | 100 |
Aztreonam | 89.7 | 88.9 | 50 | 91.9 |
Ceftazidine | 76.9 | 100 | 0 | 100 |
Ciprofloxacin | 69.2 | 66.7 | 0 | 91.9 |
Ceftriaxone | 100 | 100 | 33.3 | 100 |
Cefepime | 82.1 | 100 | 0 | 100 |
Gentamicin | 74.4 | 77.8 | 0 | 81.1 |
Imipenem | 5.1 | 33.3 | 0 | 13.5 |
Levofloxacin | 64.1 | 55.6 | 0 | 75.7 |
Ampicillin-Sulbactam | 97.4 | 100 | 33.3 | 100 |
Compound Sulfamethoxazole | 87.2 | 100 | 33.3 | 100 |
Piperacillin | 15.4 | 0 | 0 | 16.2 |
Antibiotics | Streptococcus, % (n = 20) | Coagulase-negative Staphylococcus, % (n = 11) | Enterococcus faecium, % (n = 7) |
---|---|---|---|
Ciprofloxacin | 一 | 36.4 | 100 |
Erythromycin | 55 | 72.7 | 100 |
Gentamicin | 一 | 63.6 | 85.7 |
Linezolid amide | 一 | 0 | 0 |
Levofloxacin | 5 | 36.4 | 100 |
Penicillin | 55 | 81.8 | 85.7 |
Dalfopristin | 一 | 0 | 0 |
Streptomycin | 一 | 一 | 57.1 |
Tetracyclines | 一 | 36.4 | 28.6 |
Tigecycline | 一 | 0 | 0 |
Vancomycin | 0 | 0 | 0 |
Risk factors for early BSI after UCBT
Factor | BSI (n = 92) | non-BSI (n = 244) | Univariate analysis | Multivariate analysis | |
---|---|---|---|---|---|
P
| OR (95% CI) |
P
| |||
Gender | 0.634 | ||||
Male | 57 | 158 | |||
Female | 35 | 86 | |||
Age [years] | 0.037 | 0.164 | |||
<=14 | 53 | 170 | |||
> 14 | 39 | 74 | |||
Disease | < 0.001 | 0.007 | |||
AML | 33 | 77 | |||
ALL | 34 | 143 | 0.611(0.343–1.089) | ||
CML | 8 | 8 | 1.578(0.482–5.168) | ||
MDS | 12 | 10 | 2.752(1.015–7.464) | ||
Others | 5 | 6 | 2.870(0.769–10.710) | ||
Conditioning regimen | 0.001 | 1.755(1.008–3.057) | 0.047 | ||
Not including TBI | 49 | 178 | |||
Including TBI | 43 | 66 | |||
State of disease | 0.016 | 0.640 | |||
CR or Chronic phase | 62 | 195 | |||
NR or Advanced phase | 30 | 49 | |||
HLA match (low-resolution) | 0.75 | ||||
4/6 | 33 | 80 | |||
5/6 | 46 | 122 | |||
6/6 | 13 | 42 | |||
Total nucleated-cell dose | 0.035 | 0.940 | |||
< =4.17 × 107/kg | 55 | 114 | |||
> 4.17 × 107/kg | 37 | 129 | |||
Total CD34+ cell dose | 0.079 | 0.977 | |||
< =2.32 × 105/kg | 54 | 117 | |||
> 2.32 × 105/kg | 38 | 127 | |||
Time of neutrophil recovery | < 0.001 | 1.117(1.056–1.118) | 0.000 | ||
< =17d | 34 | 150 | |||
> 17d | 58 | 94 |